Why is the Alcidion share price crashing 27% to a 52-week low?

This healthcare technology company is having a day to forget on Wednesday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Alcidion Group Ltd (ASX: ALC) share price has returned from its trading halt and sunk deep into the red.

At the time of writing, the healthcare technology company's shares are down 27% to a 52-week low of 7.1 cents.

A woman holds her hands to the side of her face as she sits back in shock at something she is reading or seeing on her computer screen.

Image source: Getty Images

What's going on with the Alcidion share price today?

There have been a couple of catalysts for the weakness in the Alcidion share price on Wednesday.

The first has been the company undertaking a capital raising. According to the release, Alcidion has received firm commitments to raise $5 million through an institutional placement. These funds are being raised at 7.5 cents per new share, which is a 23% discount to its last close price.

In addition, Alcidion is aiming to raise a further $1 million via a share purchase plan at the same price.

These funds are being raised to maintain a strong balance sheet so it can execute on its market opportunities and drive ongoing revenue growth.

What else?

The company's quarterly update doesn't appear to have gone down too well with investors and could also be weighing on the Alcidion share price today.

Alcidion reported new total contract value of $2.5 million for the quarter, which is up 39% on the prior corresponding period. This means that total contracted revenue was $35.3 million at the end of the quarter, which is up 12% on the prior corresponding period.

And while management has maintained its expectation to be EBITDA and operating cashflow positive in FY 2024, its first quarter performance is certainly not supportive of this.

Alcidion revealed quarterly cash receipts of $6.4 million and negative operating cash flow of $8 million. A big portion of this outflow relates to staff costs, which came in at a lofty $8.5 million.

This reduced its cash balance from $14.6 million at the end of June to just $6.5 million. Though, this excludes the money raised from its capital raising.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Alcidion Group. The Motley Fool Australia has recommended Alcidion Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Healthcare Shares

Is the worst over for CSL shares after this week's sell-off?

It may be too early to completely write off the biotech stock.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why are Resmed shares lagging if the business keeps compounding?

Resmed shares have had a tough time of late. But investors looking to compound returns over the long-term may want…

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 300 share crashing over 20% today?

It is a very red day for this healthcare stock. What's happening? Let's find out.

Read more »

Six smiling health workers pose for a selfie.
Broker Notes

3 reasons this beaten down ASX All Ords healthcare share could come roaring back

A leading analyst believes this beaten down ASX healthcare stock is well-positioned for a comeback.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Healthcare Shares

Down 59%: Will CSL shares ever regain momentum?

Here's what to expect over the next 12 months.

Read more »

A woman sits in front of a computer and does some calculations.
Healthcare Shares

Should you buy ResMed shares at their 52-week low?

This company is still growing, profitable, and exposed to a large sleep health market, but the share price has fallen…

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Healthcare Shares

How low can CSL shares go?

CSL shares have fallen 44% this year. Can they fall further?

Read more »

woman in lab coat conducting testing.
Healthcare Shares

3 reasons why this ASX biotech stock could double in value

Growing revenue and broker optimism are boosting confidence.

Read more »